Sunday, August 25, 2013

GLENMARK-A new way for a new world « New Drug Approvals


Undiminished zest..


“Every year we expect two more molecules to get into clinical trials,” says Saldanha, his zest undiminished by past failures. “In 2008, in a span of one or two quarters, our entire pipeline pretty much got wiped out, but we never lost our commitment and passion.” At that time its most advanced molecule, oglemilast, used for treating patients with chronic obstructive pulmonary disease, had to be abandoned when its Phase IIb trials produced unsatisfactory results. It also had to suspend clinical development of GRC 6211, a compound for treating osteoarthritis pain, because of side effects.



1 comment:

ANTHONY MELVIN CRASTO said...

MED CHEMIST is a great platform to exhibit my post about glenmark on new drug approvals..........thanks DR Umesh for the same